共 50 条
- [11] Efficacy of neoadjuvant FOLFIRINOX for borderline resectable pancreatic adenocarcinomaANNALS OF ONCOLOGY, 2016, 27Kang, J.Kim, K-P.Yoo, C.Lee, J-L.Ryoo, B-Y.Chang, H-M.Lee, S. S.Park, D. H.Song, T. J.Seo, D. W.Lee, S. K.Kim, M-H.Hwang, D. W.Song, K. B.Lee, J. H.Kim, S. C.
- [12] Neoadjuvant chemoradiation alters the immune microenvironment in pancreatic ductal adenocarcinomaONCOIMMUNOLOGY, 2022, 11 (01):Gartrell, Robyn D.Enzler, ThomasKim, Pan S.Fullerton, Benjamin T.Fazlollahi, LadanChen, Andrew X.Minns, Hanna E.Perni, SubhaWeisberg, Stuart P.Rizk, Emanuelle M.Wang, SamuelOh, Eun JeongGuo, Xinzheng, VChiuzan, CodrutaManji, Gulam A.Bates, Susan E.Chabot, JohnSchrope, BethKluger, MichaelEmond, JeanRabadan, RaulFarber, DonnaRemotti, Helen E.Horowitz, David P.Saenger, Yvonne M.
- [13] Pathologic Prognosticators for Patients with Pancreatic Ductal Adenocarcinoma Who Received Neoadjuvant FOLFIRINOX or Gemcitabine/Nab-Paclitaxel TherapyLABORATORY INVESTIGATION, 2022, 102 (SUPPL 1) : 1236 - 1236Tong, Yi TatLai, ZongshanKatz, MatthewPrakash, LauraWang, HuaChatterjee, DeyaliKim, MichaelTzeng, Ching-WeiLee, JeffreyIkoma, NaruhikoRashid, AsifWolff, Robert A.Zhao, DanKoay, EugeneMaitra, AnirbanWang, Huamin
- [14] Pathologic Prognosticators for Patients with Pancreatic Ductal Adenocarcinoma Who Received Neoadjuvant FOLFIRINOX or Gemcitabine/Nab-Paclitaxel TherapyMODERN PATHOLOGY, 2022, 35 (SUPPL 2) : 1236 - 1236Tong, Yi TatLai, ZongshanKatz, MatthewPrakash, LauraWang, HuaChatterjee, DeyaliKim, MichaelTzeng, Ching-WeiLee, JeffreyIkoma, NaruhikoRashid, AsifWolff, Robert A.Zhao, DanKoay, EugeneMaitra, AnirbanWang, Huamin
- [15] Prognosticators for Patients with Pancreatic Ductal Adenocarcinoma Who Received Neoadjuvant FOLFIRINOX or Gemcitabine/Nab-Paclitaxel Therapy and PancreatectomyCANCERS, 2023, 15 (09)Tong, Yi TatLai, ZongshanKatz, Matthew H. G.Prakash, Laura R.Wang, HuaChatterjee, DeyaliKim, MichaelTzeng, Ching-Wei D.Lee, Jeffrey E. E.Ikoma, NaruhikoRashid, AsifWolff, Robert A.Zhao, DanKoay, Eugene J.Maitra, AnirbanWang, Huamin
- [16] Clinical Efficacy of Neoadjuvant Chemotherapy with Gemcitabine plus S-1 for Resectable Pancreatic Ductal Adenocarcinoma Compared with Upfront SurgeryANNALS OF SURGICAL ONCOLOGY, 2023, 30 (8) : 5093 - 5102Kitano, YukiInoue, YosukeTakeda, TsuyoshiOba, AtsushiOno, YoshihiroSato, TakafumiIto, HiromichiOzaka, MasatoSasaki, TakashiSasahira, NaokiBaba, HideoTakahashi, Yu
- [17] Clinical Efficacy of Neoadjuvant Chemotherapy with Gemcitabine plus S-1 for Resectable Pancreatic Ductal Adenocarcinoma Compared with Upfront SurgeryAnnals of Surgical Oncology, 2023, 30 : 5093 - 5102Yuki KitanoYosuke InoueTsuyoshi TakedaAtsushi ObaYoshihiro OnoTakafumi SatoHiromichi ItoMasato OzakaTakashi SasakiNaoki SasahiraHideo BabaYu Takahashi
- [18] Pancreatic ductal adenocarcinoma: tumour regression grading following neoadjuvant FOLFIRINOX and radiationHISTOPATHOLOGY, 2020, 77 (01) : 35 - 45Neyaz, AzfarTabb, Elisabeth S.Shih, AngelaZhao, QingShroff, StutiTaylor, Martin S.Rickelt, SteffenWo, Jennifer Y.Fernandez-del Castillo, CarlosQadan, MotazHong, Theodore S.Lillemoe, Keith D.Ting, David T.Ferrone, Cristina R.Deshpande, Vikram
- [19] The Effects of Neoadjuvant Chemoradiation on Gene Expression Patterns of Pancreatic Ductal AdenocarcinomaINTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 : S360 - S361Baschnagel, A. M.Stone, B. M.Thibodeau, B. J.Fortier, L. E.Ahmed, S.Geddes, T. J.Ketelsen, B. E.Pruetz, B. L.Jury, R. P.Wilson, G. D.
- [20] SINGLE-CELL RNA SEQUENCING ANALYSIS OF PANCREATIC DUCTAL ADENOCARCINOMA REVEALS TRANSCRIPTOMIC CHANGES IN FIBROBLASTS FOLLOWING FOLFIRINOX-BASED NEOADJUVANT CHEMORADIATION THERAPYGASTROENTEROLOGY, 2021, 160 (06) : S903 - S903Harrison, JonChang, Jonathan E.Piquet, MichelleDimitrieva, SlavicaGabriel, MillicentLillemoe, Keith D.Warshaw, Andrew L.Mino-Kenudson, MariFernandez-Del Castillo, CarlosCremasco, VivianaRuddy, DaveLiss, Andrew S.